Drug profile · INN
dapagliflozin propylene glycolate hydrate
FORXIGA INITIAL APPROVAL
dapagliflozin propylene glycolate hydrate (FORXIGA INITIAL APPROVAL) is a sodium/glucose cotransporter 2 inhibitor.
PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — dapagliflozin propylene glycolate hydrate
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
dapagliflozin propylene glycolate hydrate (FORXIGA INITIAL APPROVAL) is a sodium/glucose cotransporter 2 inhibitor.
Key facts
INN dapagliflozin propylene glycolate hydrate
Brand FORXIGA INITIAL APPROVAL
Mechanism Sodium/glucose cotransporter 2 inhibitor
Target Sodium/glucose cotransporter 2
Mechanism of action
Sodium/glucose cotransporter 2 inhibitor
Primary target: Sodium/glucose cotransporter 2
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is dapagliflozin propylene glycolate hydrate?
dapagliflozin propylene glycolate hydrate (FORXIGA INITIAL APPROVAL) is a sodium/glucose cotransporter 2 inhibitor.
What is the brand name for dapagliflozin propylene glycolate hydrate?
FORXIGA INITIAL APPROVAL is a marketed brand name for dapagliflozin propylene glycolate hydrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.